Engineering GPCR signaling pathways with RASSLs
- 30 July 2008
- journal article
- review article
- Published by Springer Nature in Nature Methods
- Vol. 5 (8) , 673-678
- https://doi.org/10.1038/nmeth.1232
Abstract
We are creating families of designer G protein–coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the three major GPCR signaling pathways (Gs, Gi and Gq). We review these advances here to facilitate the use of these powerful and diverse tools.Keywords
This publication has 38 references indexed in Scilit:
- Osteoblast expression of an engineered G s -coupled receptor dramatically increases bone massProceedings of the National Academy of Sciences, 2008
- Modifying Ligand-Induced and Constitutive Signaling of the Human 5-HT4 ReceptorPLOS ONE, 2007
- Conditional Expression of a Gi-Coupled Receptor in Osteoblasts Results in Trabecular OsteopeniaEndocrinology, 2007
- High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled ReceptorScience, 2007
- Engineering the Melanocortin-4 Receptor to Control Constitutive and Ligand-Mediated Gs Signaling In VivoPLOS ONE, 2007
- Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligandProceedings of the National Academy of Sciences, 2007
- Neoceptors: reengineering GPCRs to recognize tailored ligandsTrends in Pharmacological Sciences, 2007
- Drugs and Valvular Heart DiseaseNew England Journal of Medicine, 2007
- Mining the ReceptoromePublished by Elsevier ,2005
- Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in miceNuclear Medicine and Biology, 1994